This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Aspen Pharmacare Holdings Limited

Drug Names(s): Mercaptopurine

Description: It is not known exactly which of the biochemical effects of Purinethol and its metabolites are directly or predominantly responsible for cell death. Purinethol is a purine analogue. Purines are used to form DNA and RNA, as well as other important biomolecules.

Purinethol may work by inhibiting new purine -- and hence DNA/RNA -- synthesis, purine interconversion, and incorporation into DNA and RNA as a false metabolite.

Deal Structure: In July 2003, Teva announced that it received all product rights relating to Purinethol for the United States, including Puerto Rico, and Canada from GlaxoSmithKline.

In connection with this transaction, Teva will record a one-time gain of approximately $100 million. Teva and GSK will share gross profits from the sale of Purinethol going forward at rates that may vary according to the terms of the agreement. Further details regarding this settlement remain confidential.

In May 2009, GSK announced that it will divest eight specialist medicines to Aspen Pharmacare Holdings, including Alkeran (excluding US), Leukeran, Myleran and Purinethol.

Partners: Teva Pharmaceutical Industries Ltd.

Purinethol News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug